Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2022 | SABCS 2022 highlights

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, shares his highlights from the San Antonio Breast Cancer Symposium (SABCS) 2022, including the Phase III CAPItello-291 (NCT04305496) trial demonstrating an improved progression-free survival (PFS) with the addition of capivasertib to fulvestrant in locally advanced or metastatic HR-positive, HER2-negative breast cancer and the Phase II SERENA-2 (NCT04214288) trial showing an improved PFS with camizestrant versus fulvestrant in women with advanced ER-positive HER2-negative breast cancer. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.